Therapeutics News and Research

RSS

Nanoviricides develops new drug candidates against MERS infection

...

6 May 2014

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.

6 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

UH biomedical engineer receives ALR grant to study cause of lupus nephritis

In the U.S. alone, more than 1.5 million people have lupus, a chronic autoimmune disease in which the immune system turns against itself, attacking a person's healthy tissue, cells and organs. The symptoms can range from debilitating pain and fatigue to organ failure.

6 May 2014

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.

2 May 2014

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

2 May 2014

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies.

2 May 2014

UT Southwestern docs receive grants for innovative studies on lung cancer pathways, drug therapy

Two UT Southwestern doctors have received more than a half-million dollars in grants from the Department of Defense for innovative studies on lung cancer pathways and to test the effectiveness of a potentially less expensive drug therapy.

2 May 2014

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal.

1 May 2014

Frozen meals closer to meeting Dietary Guidelines than quick service restaurant meals

New analysis of data from the 2003-2010 What We Eat In America (WWEIA) National Health and Nutrition Examination Survey (NHANES), a program of the Centers for Disease Control and Prevention (CDC), indicates that consumers of frozen meals (1) compared to consumers of quick service restaurant (QSR) meals (2) had lower calorie intakes and better Healthy Eating Index (HEI) score. In fact, the analysis revealed that those who consumed frozen meals consumed 253 fewer calories than those who consumed a quick service restaurant meal.

1 May 2014

Genzyme, Cleveland Clinic partner to develop new therapeutic approaches for MS treatment

Genzyme, a Sanofi company, announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.

30 Apr 2014

Otonomy secures $49M in oversubscribed Series D round of financing

Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round of financing.

30 Apr 2014

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Rare Disease Therapeutics, Inc. (RDT), the producer of orphan pharmaceuticals for the treatment of rare diseases, announced today that they have received FDA approval for PURIXAN™ (mercaptopurine) 20 mg/mL oral suspension---a new, easier-to-dose, liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL).

30 Apr 2014

Report focuses on behavioral issues linked with patients' self-management of type 2 diabetes

Clinical Therapeutics features a special report in its April issue focusing primarily on the behavioral issues associated with patients' self-management of type 2 diabetes.

29 Apr 2014

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

29 Apr 2014

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

29 Apr 2014

Single cell type actively suppressed in several experimental cancer vaccines

Most cancer vaccines have not lived up to their promise in clinical trials. The reason, many researchers suspect, is that the immune cells that would help the body destroy the tumor - even those reactions boosted by cancer vaccines - are actively suppressed.

29 Apr 2014

BRCA gene loss may accelerate cancer-promoting chromosome rearrangements

Inherited mutations in the BRCA1 or BRCA2 tumor suppressor genes are by far the most frequent contributors to hereditary cancer risk in the human population, often causing breast or ovarian cancer in young women of child-bearing age.

29 Apr 2014

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Highland Therapeutics Inc., an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD").

28 Apr 2014

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences.

28 Apr 2014

Therapeutics News and Research

Nanoviricides develops new drug candidates against MERS infection

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

UH biomedical engineer receives ALR grant to study cause of lupus nephritis

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

UT Southwestern docs receive grants for innovative studies on lung cancer pathways, drug therapy

Biotech to the rescue

Frozen meals closer to meeting Dietary Guidelines than quick service restaurant meals

Genzyme, Cleveland Clinic partner to develop new therapeutic approaches for MS treatment

Otonomy secures $49M in oversubscribed Series D round of financing

RDT receives FDA approval for new liquid form of treatment for patients with ALL

Report focuses on behavioral issues linked with patients' self-management of type 2 diabetes

Cell Therapeutics announces launch of PIXUVRI in the UK for treatment of aggressive B-cell NHL

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Single cell type actively suppressed in several experimental cancer vaccines

BRCA gene loss may accelerate cancer-promoting chromosome rearrangements

Highland subsidiary begins enrolment in Phase III study of HLD-200 in pediatric ADHD patients

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News